Adipose Inflammation and Diabetes (FAB)

Recruiting

• Conditions: Obese

• Registration Number: NCT04255264
• Lead Sponsor: Göteborg University

Brief Summary

The study investigates whether the addition of resolution molecules can inhibit inflammation and insulin resistance in human tissue taken from obese individuals, and whether the results of these studies correlate with patient-specific resolution phenotypes.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-08-01
• Study First Submitted: 2020-02-03
• Study First Submitted QC: 2020-02-03
• Study First Posted: 2020-02-05
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-05
• Last Update Posted: 2025-05-06
• Primary Completion: 2026-06-30
• Study Completion: 2027-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• BMI 30-40 kg/m2
• Ptos (i.e. excess skin) > 3 cm
• Patient underwent gastric bypass surgery >2 years ago
• Patient has had a stable weight ≥6 months at the time of operation
• Patient does not smoke (min 6 weeks prior to surgery)

Exclusion Criteria

• Patients who do not understand spoken and written Swedish
• American Society of Anesthesiologists (ASA) classification ≥ 3
• Neurological, orthopedic or rheumatologic injury or illness affecting physical ability
• Preoperatively known hernia requiring surgical operation
• Severe mental illness

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Inflammatory status	2025	The inflammatory status will be studied in obese patients.

Trial Locations

Locations (1)

Sahlgrenska university hospital; 🇸🇪 Gothenburg, Vastra Gotaland, Sweden